Top Markets
Coin of the day
Hemagen Diagnostics, Inc. Hemagen Diagnostics, Inc.

Hemagen Diagnostics, Inc.

HMGN
Rangering i aksjer #42231
Hemagen Diagnostics, Inc., a global biotechnology firm, specializes in... Hemagen Diagnostics, Inc., a global biotechnology firm, specializes in delivering clinical diagnostic solutions for both human and animal health. The company designs, manufactures, and distributes the VIRGO product line, a series of human clinical immunoassays used for identifying autoimmune and infectious diseases, as well as acute phase proteins. Its comprehensive human diagnostic portfolio also encompasses Universal IFA components, various supplies, controls, calibrators, accessories, H-rotors, reagents, electrodes, equipment, and specialized assays covering conditions such as Chagas, acute phase proteins, and cytokines. For the veterinary market, Hemagen Diagnostics provides diagnostic equipment, reagents, consumables, accessories, and electrodes crucial for chemistry, hematology, and electrolyte analysis. The company reaches a diverse customer base, including laboratories, hospitals, and blood banks, through both direct sales and an extensive distribution network. Established in 1985, Hemagen Diagnostics maintains its headquarters in Columbia, Maryland.
Aksjekurs
$0.0002
Sist synkronisert: 2026-08-11
Markedsverdi
$3.10K
Endring (1 dag)
0.00%
Endring (1 år)
-98.67%
Land
US
Handel Hemagen Diagnostics, Inc. (HMGN)

Kategori

Inntekter for Hemagen Diagnostics, Inc. (HMGN)
Inntekter i 2026 TTM: 0
Ifølge Hemagen Diagnostics, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Hemagen Diagnostics, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -
US
$1.95B -
NL
- -
CH
$3.01B -
BE
- -
KR